For patients 6 years and older with moderate to severe plaque psoriasis
Thank you for your expertise in treating autoimmune/autoinflammatory diseases. The arrival of COVID-19 has increased the complexity of your calling, and we want to acknowledge you for the deep commitment you have to your patients.
What does the availability of COVID-19 vaccines mean for patients taking COSENTYX® (secukinumab)?
According to the COSENTYX Prescribing Information, prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX
As of June 24, 2021, all COVID-19 vaccines with emergency use authorization are non-live vaccines, and at this time, there are no live COVID-19 vaccines in phase 3 clinical development1
What does COVID-19 mean for patients taking COSENTYX?
At this time, Novartis does not have data on patients with COVID-19 who start or continue on COSENTYX
COSENTYX may increase the risk of infections. Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurring infection2
Instruct patients to seek medical advice if signs and symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves2
Availability & Manufacturing
Secukinumab is manufactured in France and Switzerland in sterile, state-of-the-art manufacturing facilities3
At this time, Novartis Pharmaceuticals Corporation does not anticipate supply chain disruption due to the COVID-19 outbreak. We are confident that our existing stock is sufficient to cover production/distribution needs for the time being
Where required, we have enacted mitigation plans to ensure ongoing drug supply4
The quality, safety, and efficacy of our products are of fundamental importance to Novartis, and we are committed to ensuring that all our marketed products meet the highest quality standards
Please refer to the following:
Novartis COVID-19 Information Center ↗
American Academy of Dermatology ↗
American College of Rheumatology ↗
US Centers for Disease Control and Prevention ↗
World Health Organization ↗
For additional questions regarding this information, please contact Novartis Medical Information @ 1-888-NOW-NOVA (1-888-669-6682) from Monday - Friday, 8:30 AM - 5:00 PM ET.